Vinflunine: a novel antitubulin agent in solid malignancies.
Vinflunine is the first bi-fluorinated, tubulin-targeted agent that was obtained by semisynthesis using super-acidic chemistry, which allowed the selective introduction of two fluorine atoms at the C20' position of vinorelbine. This compound has been selected for clinical development on the basis of promising preclinical activity that warranted a study in patients with a wide spectrum of solid tumours. Clinically significant activity was seen in the Phase II studies for the treatment of bladder, non-small cell lung and breast cancers, thus prompting the initiation of the Phase III trials that are currently ongoing.
Bennouna
Jaafar
J
Centre René Gauducheau, Saint-Herblain, France. j-bennouna@nantes.fnclcc.fr
Campone
Mario
M
Delord
Jean Pierre
JP
Pinel
Marie-Claire
MC
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D050257:Tubulin Modulators / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
D000970:Antineoplastic Agents; D050257:Tubulin Modulators; C111217:vinflunine; D014747:Vinblastine